Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression

Virology

Volumn 379, Issue 1, 2008, Pages 20-29

  Morandell, Dieter ^a,b   Rostek, Ursula ^a   Bouvard, Veronique ^c   Campo Fernández, Beatriz ^a,b   Fiedler, Marc ^a,b   Jansen Dürr, Pidder ^a,d   Zwerschke, Werner ^a,b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cell proliferation; Cell transformation; Cervical cancer; HPV 45 E7 oncoprotein; Human papillomavirus; Retinoblastoma protein

Indexed keywords

EPOXOMICIN; RETINOBLASTOMA PROTEIN; TRANSFORMING PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL TRANSFORMATION; FIBROBLAST; GENOTYPE; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN PAPILLOMA VIRUS 45; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; VIRUS ONCOGENE; WART VIRUS; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; CELL CYCLE; CELL LINE; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; KERATINOCYTES; MICE; MODELS, MOLECULAR; MUTATION, MISSENSE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RETINOBLASTOMA PROTEIN; SEQUENCE ALIGNMENT; SEQUENCE DELETION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 45; PAPILLOMAVIRIDAE;

EID: 49049095064     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.06.004     Document Type: Article

References (67)

1. Barbosa M.S., and Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 4 (1989) 1529-1532
2. Berezutskaya E., and Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J. Biol. Chem. 272 (1997) 30135-30140
3. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., and Shah K.V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87 (1995) 796-802
4. Boyer S.N., Wazer D.E., and Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56 (1996) 4620-4624
5. Chellappan S.V., Kraus B., Kroger K., Munger K., Howley P.M., Phelps W.C., and Nevins J.R. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. USA 89 (1992) 4549-4553
6. Ciccolini F., Di Pasquale G., Carlotti F., Crawford L., and Tommasino M. Functional Studies of E7 proteins from different HPV-types. Oncogene 9 (1994) 2342-2348
7. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV-type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89 (2003) 101-105
8. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1157-1164
9. Clifford G., Franceschi S., Diaz M., Muñoz N., and Villa L.L. Chapter 3: HPV-type-distribution in women with and without cervical neoplastic diseases. Vaccine. 24S3 (2006) S26-S34
10. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 24 (2005) 2796-2809
11. Cole S.T., and Danos O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J Mol Biol. 193 (1987) 599-608
12. Crook T.J., Morgenstern P., Crawford L., and Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 8 (1989) 513-519
13. Demers G.W., Foster S.A., Halbert C.L., and Galloway D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA. 91 (1994) 4382-4386
14. De Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
15. Dürst M., Glitz D., Schneider A., and zur Hausen H. Human papillomavirus type (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189 (1992) 132-140
16. Dyson N., Howley P.M., Münger K., and Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (1989) 934-937
17. Fiedler M., Muller-Holzner E., Viertler H.P., Widschwendter A., Laich A., Pfister G., Spoden G.A., Jansen-Durr P., and Zwerschke W. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J. 18 (2004) 1120-1122
18. Fiedler M., Ressler S., Campo-Fernandez B., Laich A., Jansen L., Widschwendter A., Viertler H.P., Bacher N., Morandell D., Muller-Holzner E., Durst M., Jansen-Durr P., and Zwerschke W. Expression of the high-risk human papillomavirus type 18 and 45 E7 oncoproteins in cervical carcinoma biopsies. J. Gen. Virol. 86 (2005) 3235-3241
19. Geisbill J., Osmers U., and Dürst M. Detection and characterization of human papillomavirus type 45 DNA in the cervical carcinoma cell line MS751. J. Gen. Virol. 78 (1997) 655-658
20. Giarre M., Caldeira S., Malanchi I., Ciccolini F., Leao M.J., and Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J. Virol. 75 (2001) 4705-4712
21. Gonzalez S.L., Stremlau M., He X., Basile J.R., and Münger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoproiein is important for functional inactivation and is separable from proleasomal degradation of E7. J. Virol. 75 (2001) 7583-7591
22. Greenfield I., Nickerson J., Penman S., and Stanley M. Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc. Natl. Acad. Sci. USA 88 (1991) 11217-11221
23. Guadagno T., Ohtsubo M., Roberts J.M., and Assoian R. A link between cyclin A expression and adhesion-dependent cell cycle progression. Science 262 (1993) 1157-1572
24. Halbert C.L., Demers G.W., and Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65 (1991) 473-478
25. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., and Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8 (1989) 3905-3910
26. Helt A., and Galloway D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 75 (2001) 6737-6747
27. Hu T.H., Ferril S.C., Snider A.M., and Barbosa M.S. In vivo analysis of HPV E7 protein association with pRb, p107 and p130. Int. J. Oncol. 6 (1995) 167-174
28. Hudson J.B., Bedell M.A., McCance D.J., and Laiminis L.A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J. Virol. 64 (1990) 519-526
29. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81 (2007) 9737-9747
30. Imai Y., Matsushima Y., Sugimura T., and Terada M. Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J Virol. 65 (1991) 4966-4972
31. Jewers R., Hildebrandt P., Ludlow J., Kell B., and McCance D.J. Regions of HPV 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol. 66 (1992) 1329-1335
32. Jones D.L., and Münger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J. Virol. 71 (1997) 2905-2912
33. Jones D.L., Thompson D.A., and Münger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV-type 16 E7-induced apoptosis. Virology 239 (1997) 97-107
34. Lee J.O., Russo A.A., and Pavletich N.P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391 (1998) 859-865
35. Ludlow J.W., DeCaprio J.A., Huang C.M., Lee W.H., Paucha E., and Livingston D.M. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 56 (1989) 57-65
36. Mannhardt B., Weinzimer S.A., Wagner M., Fiedler M., Cohen P., Jansen-Durr P., and Zwerschke W. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol. Cell Biol. 20 (2000) 6483-6495
37. Massimi P., Pim D., and Banks L. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J. Gen. Virol. 78 (1997) 2607-2613
38. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., and Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96 (1999) 10403-10408
39. Morozov J.R., Raychaudhuri P., and Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ. 8 (1997) 1277-1286
40. Münger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 89 (2002) 213-228
41. Münger K., Phelps W.C., Bubb V., Howley P.M., and Schlegel R. The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63 (1989) 4417-4421
42. Münger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., and Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8 (1989) 4099-4105
43. Muñoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsagué X., Shah K.V., Díaz M., Snijders P.J., and Meijer C.J. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 (2003) 518-527
44. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D., Shah K.`V., and Meijer C.J. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 (2004) 278-285
45. Naghashfar Z.S., Rosenshein N.B., Lorincz A.T., Buscema J., and Shah K.V. Characterization of human papillomavirus type 45, a new type 18-related virus of the genital tract. J. Gen. Virol. 68 (1987) 3073-3079
46. Nauenburg S., Zwerschke W., and Jansen-Dürr P. Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J. 15 (2001) 592-594
47. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139 (1991) 271-279
48. Ohlenschlager O., Seiboth T., Zengerling H., Briese L., Marchanka A., Ramachandran R., Baum M., Korbas M., Meyer-Klaucke W., Dürst M., and Görlach M. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 25 (2006) 5953-5959
49. Patrick D.R., Oliff A., and Heimbrook D.C. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 269 (1994) 6842-6850
50. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90 (1993) 8392-8396
51. Phelps W.C., Münger K., Yee C.L., Barnes J.A., and Howley P.M. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 66 (1992) 2418-2427
52. Raychaudhuri P., Bagchi S., Devoto S.H., Kraus V.B., Moran E., and Nevins J.R. Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes. Genes Dev. 5 (1991) 1200-1211
53. Ressler S., Scheiden R., Dreier K., Laich A., Müller-Holzner E., Pircher H., Morandell D., Stein I., Viertler H.P., Santer F.R., Widschwendter A., Even J., Jansen-Dürr P., Capesius C., and Zwerschke W. High-risk HPV E7 oncoprotein expression in cervical squamous cell carcinoma. Clin. Can. Res. 13 (2007) 7067-7072
54. Reznikoff C.A., Belair C., Savelieva E., Zhai Y., Pfeifer K., Yeager T., Thompson K.J., DeVries S., Bindley C., Newton M.A., Sekhon G., and Waldman F. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev. 8 (1994) 2227-2240
55. Riley R., Duensing S., Brake T., Münger K., Lambert P.F., and Arbeit J. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 63 (2003) 4862-4871
56. Santer F.R., Bacher N., Moser B., Morandell D., Ressler S., Firth S.M., Spoden G.A., Sergi C., Baxter R.C., Jansen-Dürr P., and Zwerschke W. Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Res. 66 (2006) 3024-3033
57. Schulze A., Mannhardt B., Zerfass-Thome K., Zwerschke W., and Jansen-Dürr P. Anchorage-independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16. J Virol. 72 (1998) 2323-2334
58. Smotkin D., and Wettstein F.O. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 61 (1997) 1686-1689
59. Stoler M.H., Rhodes C.R., Whitbeck A., Wolinsky S.M., Chow L.T., and Broker T.R. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23 (1992) 117-128
60. Ullman C.G., Haris P.I., Galloway D.A., Emery V.C., and Perkins S.J. Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7. Biochem. J. 319 (1996) 229-239
61. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., and Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
62. Wang J., Sampath A., Raychaudhuri P., and Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 20 (2001) 4740-4749
63. Wazer D.E., Liu X., Chu Q., Gao Q., and Band V. Immortalization of distinct human mammary epithelial cell types by human papillomavirus 16 E6 or E7. Proc. Natl. Acad. Sci. USA 92 (1995) 3687-3691
64. Wu E.W., Clemens K.E., Heck D.V., and Münger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol. 67 (1993) 2402-2407
65. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin. Cancer Biol. 9 (1999) 405-411
66. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350
67. Zwerschke W., and Jansen-Dürr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv. Cancer Res. 78 (2000) 1-29